355836-08-7Relevant academic research and scientific papers
NLRP3 INFLAMMASOME INHIBITORS
-
Paragraph 0710-0711, (2020/12/04)
The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammaso
A transition metal complex compound, and the compound of the catalyst and a catalyst for large amt. pentavelent carried out in the presence of an olefin multimer manufacturing method
-
Paragraph 0174-0176, (2019/08/28)
PROBLEM TO BE SOLVED: To provide a transition metal complex compound, to provide an olefin polymerizing catalyst, containing the compound, and having excellent activity, and to provide a method for producing the olefin polymer which is carried out in the presence of the catalyst.SOLUTION: There is provided the transition metal complex compound of compound 3, e.g. of chemical formula; and the olefin polymerizing catalyst including following components (A) and (B): (A) the transition metal compound; and (B) at least one compound selected from the group consisting of (B-1) an organometallic compound, (B-2) an organoaluminumoxy compound, and (B-3) a compound reactive with the transition metal compound (A), and forming an ion pair.
2-Arylpyrimidines: Novel CRF-1 receptor antagonists
Yoon, Taeyoung,De Lombaert, Stephane,Brodbeck, Robbin,Gulianello, Michael,Krause, James E.,Hutchison, Alan,Horvath, Raymond F.,Ge, Ping,Kehne, John,Hoffman, Diane,Chandrasekhar, Jayaraman,Doller, Dario,Hodgetts, Kevin J.
scheme or table, p. 4486 - 4490 (2009/04/08)
The design, synthesis and structure-activity relationship studies of a novel series of CRF-1 receptor antagonists, the 2-arylpyrimidines, are described. The effects of substitution on the aromatic ring and the pyrimidine core on CRF-1 receptor binding wer
